Navigation Links
Ceres Announces Fiscal Third Quarter 2014 Financial Results
Date:7/10/2014

ts of operations and financial position, including anticipated cost savings from the company's plan to align expenditures, are forward-looking statements. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Ceres' control. Factors that could materially affect actual results can be found in Ceres' filings with the U.S. Securities and Exchange Commission. Ceres undertakes no obligation to update publicly, except to the extent required by law, any forward-looking statements for any reason after the date the company issues this press release to conform these statements to actual results or to changes in the company's expectations.

 CERES, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Operations (In thousands, except share and per share amounts)(Unaudited) Three Months Ended
May 31,  Nine Months Ended
May 31, 2014201320142013Revenues:Product sales 

$
3
$
389
$
229
$
462
Collaborative research and government grants 

6439661,8353,884Total revenues 

8061,3552,0644,346Cost and operating expenses:Cost of product sales 

5752,1342,4405,114Research and development 

'/>"/>

SOURCE Ceres, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
2. Ceres Receives $3.5 million from USAID for Trait Stacks
3. Ceres and Syngenta to Collaborate on Sweet Sorghum Market Development
4. Ceres Announces Webcast of Fiscal Year 2013 Financial Results
5. Ceres Announces Fiscal Year 2013 Financial Results
6. Ceres Announces Fiscal First Quarter 2014 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
9. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
10. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
11. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... NEEDHAM, Mass., Jan. 22 Hospitals and ... procedures that allow,construction projects to take place ... free white paper that addresses these challenges ... The white paper, titled "Infection Control ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... with,Ortho Women,s Health & Urology, Division of ... settle the,outstanding patent litigation involving Ortho Women,s ... LO (norgestimate/ethinyl,estradiol). The United States District Court ...
... Speed in Reaching First Clinical Milestone Validates Approach, ... today,announced the successful completion of its first clinical ... for SYN-111,(rufinamide), a sodium channel blocker. Rufinamide was ... by Eisai in Europe as a,drug to treat ...
Cached Biology Technology:White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 3Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... altered osteoporosis drug may be useful in fighting malaria, researchers ... other parasitic protozoa, the drug readily crosses into the red ... The drug works at very low concentrations with no observed ... Proceedings of the National Academy of Sciences . ...
... A group of scientists from across the world have come ... into how fructose causes obesity and metabolic syndrome, more commonly ... performed in lab animals, researchers found that fructose can be ... One form appears to be responsible for causing how fructose ...
... CA--A study of the tropical coral reef system along the ... could threaten the long-term health of the reefs. Led by ... was published in the journal Coral Reefs (online ... loss of predatory fish leads to a cascade of effects ...
Cached Biology News:Modified bone drug kills malaria parasite in mice 2Research offers insight to how fructose causes obesity and other illness 2Coral reef study traces indirect effects of overfishing 2
Rabbit polyclonal to Kallikrein 1 ( Abpromise for all tested applications). Antigen: Full length native kallikrein from tissue (Human) Entrez Gene ID: 3816 Swiss Protein ID: P06870...
Biotin d anti-mouse Tim-1...
... Kir2.1 protein. The epitope is specific ... in any other known protein.,SPECIES REACTIVITIES: ... in rabbit, bovine, porcine and guinea ... rat and mouse (17/19 residues) and ...
Mouse monoclonal [J53] to Thyroid Hormone Receptor beta 1 ( Abpromise for all tested applications). entrezGeneID: 7068 SwissProtID: P10828...
Biology Products: